IP Library Patent Application 12842661
Patent Application
App. No. 12/842,661

TOPICAL ANTI-INFLAMMATORY COMPOSITION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/842,661
Abstract

Compositions and methods for treating inflammation in mammalian tissue are provided using substantially continuously, in situ generated, anti-inflammatory effective amounts of hydrogen peroxide.

Claims (41)

1 . A method of treating inflammation in a mammalian tissue comprising administering to said tissue a composition capable of substantially continuously generating an anti-inflammatory effective amount of hydrogen peroxide in situ.

2 . The method of claim 1 , wherein said inflammation is sub-clinical inflammation.

3 . The method of claim 1 , wherein said inflammation is clinical inflammation.

4 . The method of claim 1 , wherein said composition comprises a hydrogen peroxide generating agent selected from the group consisting of galvanic particulates, vitamins, metal oxides, enzymes and their substrates, and combinations thereof.

5 . The method of claim 1 wherein said composition comprises galvanic particulates.

6 . The method of claim 5 , wherein said galvanic particulates comprise a first conductive material and a second conductive material, wherein both said first conductive material and said second conductive material are exposed on the surface of said galvanic particulates, the particle size of said galvanic particulates is from about 10 nanometers to about 100 micrometers, and the difference in Standard Potentials of said first conductive material and said second conductive material is at least about 0.2 V.

7 . The method of claim 6 , wherein said galvanic particulates comprise said first conductive material partially coated with said second conductive material.

8 . The method of claim 5 , wherein said galvanic particulates comprise at least 95 percent, by weight, of said first conductive material and said second conductive material.

9 . The method of claim 5 , wherein said first conductive material is zinc.

10 . The method of claim 5 , wherein said second conductive material is copper or silver.

11 . The method of claim 1 , wherein said composition comprises at least one vitamin and said composition is administered with blue, visible, or sun light.

12 . The method of claim 1 , wherein said composition comprises at least one metal oxide and said composition is administered with ultraviolet or visible light.

13 . The method of claim 1 , wherein said composition comprises at least one enzyme and its substrate.

14 . The method of claim 1 , wherein said anti-inflammatory effective amount is less than about 0.5% by weight of the composition.

15 . The method of claim 1 , wherein said anti-inflammatory effective amount is about 0.0001 to about 0.5% by weight of the composition.

16 . The method claim 1 , wherein said tissue is selected from the group consisting of epidermis and epithelial tissue.

17 . A method of substantially continuously generating hydrogen peroxide in situ on a mammalian tissue, which comprises contacting said tissue with a composition comprising a hydrogen peroxide generating agent selected from the group consisting of galvanic particulates, vitamins, metal oxides, enzymes and their substrates, and combinations thereof.

18 . The method of claim 17 , wherein said composition comprises galvanic particulates that comprise a first conductive material and a second conductive material, wherein both said first conductive material and said second conductive material are exposed on the surface of said galvanic particulates, the particle size of said galvanic particulates is from about 10 nanometers to about 100 micrometers, and the difference in Standard Potentials of said first conductive material and said second conductive material is at least about 0.2 V.

19 . The method of claim 18 , wherein said galvanic particulates comprise said first conductive material partially coated with said second conductive material.

20 . The method of claim 18 , wherein said galvanic particulates comprise at least 95 percent, by weight, of said first conductive material and said second conductive material.

21 . The method of claim 18 , wherein said first conductive material is zinc.

22 . The method of claim 18 , wherein said second conductive material is copper or silver.

23 . The method of claim 17 , wherein said composition comprises at least one vitamin and said composition is administered with blue, visible, or sun light.

24 . The method of claim 17 , wherein said composition comprises at least one metal oxide and said composition is administered with ultraviolet or visible light.

25 . The method of claim 17 , wherein said composition comprises at least one enzyme and its substrate.

26 . The method claim 17 , wherein said tissue is selected from the group consisting of epidermis and epithelial tissue.

27 . An anti-inflammatory composition capable of substantially continuously generating an anti-inflammatory effective amount of hydrogen peroxide in mammalian tissues in situ.

28 . The composition of claim 27 comprising a carrier suitable for topical administration.

29 . The composition of claim 27 comprising a carrier suitable for gastrointestinal administration.

30 . The composition of claim 27 comprising a hydrogen peroxide generating agent selected from the group consisting of galvanic particulates, vitamins, metal oxides, enzymes and their substrates, and combinations thereof.

31 . The composition of claim 27 comprising galvanic particulates.

32 . The composition of claim 31 , wherein said galvanic particulates comprise a first conductive material and a second conductive material, wherein both said first conductive material and said second conductive material are exposed on the surface of said galvanic particulates, the particle size of said galvanic particulates is from about 10 nanometers to about 100 micrometers, and the difference in Standard Potentials of the first conductive material and the second conductive material is at least about 0.2 V.

33 . The composition of claim 32 , wherein said galvanic particulates comprise said first conductive material partially coated with said second conductive material.

34 . The composition of claim 31 , wherein said galvanic particulates comprise at least 95 percent, by weight, of said first conductive material and said second conductive material.

35 . The composition of claim 31 , wherein said first conductive material is zinc.

36 . The composition of claim 31 , wherein said second conductive material is copper or silver.

37 . The composition of claim 27 comprising at least one vitamin, wherein said composition is administered with blue, visible, or sun light.

38 . The composition of claim 27 comprising at least one metal oxide, wherein said composition is administered with ultraviolet or visible light.

39 . The composition of claim 27 comprising at least one enzyme and its substrate.

40 . The composition of claim 27 , wherein said anti-inflammatory effective amount is less than about 0.5% by weight of the composition.

41 . The composition of claim 27 , wherein said anti-inflammatory effective amount is about 0.0001 to about 0.5% by weight of the composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2010
From: CHANTALAT, JEANNETTE; LIU, JUE-CHEN; SHANA'A, MAY; SOUTHALL, MICHAEL; SUN, YING
To: JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
Reel/Frame 025312/0920 →